Those who are paid to love it, by a wide margin.
This brief evaluation, published in Annals of Internal Medicine, asks the question: is there a relationship between financial conflicts-of-interest, and the outcomes of systematic reviews regarding the use of neuraminidase inhibitors for influenza? To answer such a question, these authors reviewed 37 assessments in 26 systematic reviews, published between 2005 and 2014, and evaluated the concluding language of each as “favorable” or “unfavorable”. They then checked each author of each systematic review for relevant conflicts of interest with GlaxoSmithKline and Roche Pharmaceuticals.
Among those systematic reviews associated with author COI, 7 of 8 assessments were rated as “favorable”. Among the remaining 29 assessments made without author COI, only 5 were favorable. Of the reviews published with COI, only 1 made mention of limitations due to publication bias or incomplete outcomes reporting, versus most of those published without COI.
Shocking findings to all frequent readers, I’m sure.
“Financial Conflicts of Interest and Conclusions About Neuraminidase Inhibitors for Influenza”
Original link in error … although, it’s a good article, too!